129 related articles for article (PubMed ID: 36928309)
1. Ocular Surface Metrics in Blepharospasm Patients After Treatment With Botulinum Toxin Injections.
Yabumoto C; Osaki MH; Osaki T; Gameiro GR; Campos M; Osaki TH
Ophthalmic Plast Reconstr Surg; 2023 Sep-Oct 01; 39(5):475-478. PubMed ID: 36928309
[TBL] [Abstract][Full Text] [Related]
2. Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm.
Park DI; Shin HM; Lee SY; Lew H
Acta Ophthalmol; 2013 Mar; 91(2):e108-12. PubMed ID: 23425111
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye.
Horwath-Winter J; Bergloeff J; Floegel I; Haller-Schober EM; Schmut O
Br J Ophthalmol; 2003 Jan; 87(1):54-6. PubMed ID: 12488263
[TBL] [Abstract][Full Text] [Related]
4. Tear meniscus, corneal topographic and aberrometric changes after botulinum toxin-a injection in patients with blepharospasm and hemifacial spasm.
Bayraktar Bilen N; Bilen Ş; Topçu Yılmaz P; Evren Kemer Ö
Int Ophthalmol; 2022 Aug; 42(8):2625-2632. PubMed ID: 35355169
[TBL] [Abstract][Full Text] [Related]
5. Smartphone and custom-made software to assess the effect of botulinum toxin in essential blepharospasm: Initial results.
Yabumoto C; Osaki MH; Gameiro GR; Matayoshi S; Campos M; Osaki TH
Eur J Neurol; 2023 Apr; 30(4):887-891. PubMed ID: 36583629
[TBL] [Abstract][Full Text] [Related]
6. [Botulinum toxin type A influence on the lacrimal function of patients with facial dystonia].
Oliveira FC; Oliveira GC; Cariello AJ; Felberg S; Osaki MH
Arq Bras Oftalmol; 2010; 73(5):405-8. PubMed ID: 21225122
[TBL] [Abstract][Full Text] [Related]
7. The influence of benign essential blepharospasm on dry eye disease and ocular inflammation.
Lu R; Huang R; Li K; Zhang X; Yang H; Quan Y; Li Q
Am J Ophthalmol; 2014 Mar; 157(3):591-7.e1-2. PubMed ID: 24269849
[TBL] [Abstract][Full Text] [Related]
8. Changes in ocular higher-order aberrations following botulinum toxin treatment in patients with blepharospasm : BTX improves dry eye in patients with BEB.
Isshiki Y; Ishikawa H; Mimura O
Jpn J Ophthalmol; 2016 Nov; 60(6):486-491. PubMed ID: 27503401
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of tear abnormalities associated with benign essential blepharospasm and amelioration by means of botulinum toxin type A treatment.
Hosotani Y; Yokoi N; Okamoto M; Ishikawa H; Komuro A; Kato H; Mimura O; Gomi F
Jpn J Ophthalmol; 2020 Jan; 64(1):45-53. PubMed ID: 31823132
[TBL] [Abstract][Full Text] [Related]
10. Corneal and Tear Film Changes After Botulinum Toxin-A in Blepharospasm or Hemifacial Spasm.
Gunes A; Demirci S; Koyuncuoglu HR; Tok L; Tok O
Cornea; 2015 Aug; 34(8):906-10. PubMed ID: 26075455
[TBL] [Abstract][Full Text] [Related]
11. [Lacrimal film evaluation of patients with facial dystonia during botulinum toxin type A treatment].
Costa PG; Cardoso IP; Saraiva FP; Raiza AC; Tanaka LK; Matayoshi S
Arq Bras Oftalmol; 2006; 69(3):319-22. PubMed ID: 16936952
[TBL] [Abstract][Full Text] [Related]
12. [Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review].
Schellini SA; Matai O; Igami TZ; Padovani CR; Padovani CP
Arq Bras Oftalmol; 2006; 69(1):23-6. PubMed ID: 16491229
[TBL] [Abstract][Full Text] [Related]
13. Ocular surface alterations in blepharospasm patients treated with botulinum toxin A injection.
Kocabeyoglu S; Sekeroglu HT; Mocan MC; Muz E; Irkec M; Sanac AS
Eur J Ophthalmol; 2014; 24(6):830-4. PubMed ID: 24803156
[TBL] [Abstract][Full Text] [Related]
14. Clinical Analysis of Patients with Primary Blepharospasm: A Report of 100 Cases in China.
Huang XF; Wang KY; Liang ZH; Du RR; Zhou LN
Eur Neurol; 2015; 73(5-6):337-41. PubMed ID: 25997849
[TBL] [Abstract][Full Text] [Related]
15. Ocular surface status in patients with hemifacial spasm under long-lasting treatment with botulinum A toxin: A comparative fellow eye study.
Pellegrini M; Schiavi C; Taroni L; Sebastiani S; Bernabei F; Roda M; Moscardelli F; Giannaccare G
Indian J Ophthalmol; 2019 Sep; 67(9):1405-1409. PubMed ID: 31436182
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
Ababneh OH; Cetinkaya A; Kulwin DR
Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
[TBL] [Abstract][Full Text] [Related]
17. Objective demonstration of eyelid spasm relief with smartphone and custom software in hemifacial spasm patients.
Gameiro GR; Yabumoto C; Osaki MH; Monteiro LG; Schor P; Osaki TH
Int Ophthalmol; 2024 Mar; 44(1):144. PubMed ID: 38498055
[TBL] [Abstract][Full Text] [Related]
18. Effect of eyelid botulinum toxin injection on lacrimal drainage.
Sahlin S; Chen E; Kaugesaar T; Almqvist H; Kjellberg K; Lennerstrand G
Am J Ophthalmol; 2000 Apr; 129(4):481-6. PubMed ID: 10764857
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the effects of Botulinum Toxin A on tear metrics in patients with hemifacial spasm.
Mali YP; Schultze RL; Wladis EJ
Orbit; 2017 Oct; 36(5):307-310. PubMed ID: 28627956
[TBL] [Abstract][Full Text] [Related]
20. An objective tool to measure the effect of botulinum toxin in blepharospasm and hemifacial spasm.
Osaki MH; Osaki TH; Garcia DM; Osaki T; Gameiro G; Belfort R; Cruz AAV
Eur J Neurol; 2020 Aug; 27(8):1487-1492. PubMed ID: 32294304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
